Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

NCT ID: NCT02631954

Last Updated: 2020-03-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2015-11-30

Brief Summary

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

Detailed Description

To healthy volunteers subjects of twenty four(24), following treatments are administered dosing in each period injected wash-out period is a minimum of 7days. Treatment A(Test Drug): Vorico Injection 200mg(Voriconazole) for Single Dose Treatment B(Reference Drug): Vfend® IV 200mg for Single Dose Pharmacokinetic blood samples are collected up to 24hrs.

Safety and pharmacokinetic are assessed.

Conditions

Aspergillus Infections; Candida Infections; Fungal Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TR Group

Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg

Group Type: EXPERIMENTAL

Vorico Injection 200mg(Voriconazole)

Intervention Type: DRUG

Vorico Injection 200mg(Voriconazole) to administered intravenously once

Vfend®(Voriconazole) IV 200mg

Intervention Type: DRUG

Vfend®(Voriconazole) IV 200mg to administered intravenously once

RT group

Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)

Group Type: EXPERIMENTAL

Vorico Injection 200mg(Voriconazole)

Intervention Type: DRUG

Vorico Injection 200mg(Voriconazole) to administered intravenously once

Vfend®(Voriconazole) IV 200mg

Intervention Type: DRUG

Vfend®(Voriconazole) IV 200mg to administered intravenously once

Interventions

Vorico Injection 200mg(Voriconazole)

Vorico Injection 200mg(Voriconazole) to administered intravenously once

Intervention Type: DRUG

Vfend®(Voriconazole) IV 200mg

Vfend®(Voriconazole) IV 200mg to administered intravenously once

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. A healthy person whose age is in between 19 to 55 during the screening tests

2. Whose weight is more than 55 kg, BMI is over 18.5 and under 30.0 during the screening test. (BMI (kg/m2) = weight (kg) / {height (m)}2)

3. Who is completely informed and understand about this clinical trial, voluntarily participating it, and signed to follow the given instructions

4. Who is proven to fit into the clinical trial following by physical examination, ECG (electrocardiogram), clinical laboratory test, medical examination

5. Who agreed to do birth control during testing

• A male who did not have vasectomy has to follow the clinically proven contraceptive methods* listed under, and who agreed not to donate sperm during the test

• Clinically proven contraceptive method: intrauterine device (ex. Lippes Loop, Minera), chemical contraceptive (spermicides) for use with physical contraceptive method (males or females), contraceptive implants (ex. Implanon), tubal ligation or laparoscopy (common methods of tubal ligation)
• A woman of childbearing age who agreed on constant use of a medically disproven Dual Protection method** and spermicides except hormonal contraceptive, and who also agreed not to breastfeed.

• A Dual Protection method: use of condoms, the Intrauterine Contraceptive Device, the diaphragm, the cervical cap, in the case where a sexual partner had vasectomy over 3 months ago (from the date of initial screening) or a sexual partner had been medically diagnosed sterile.

Exclusion Criteria

1. A person who has a history of clinically significant cardiovascular, respiratory, liver, kidney, endocrine system, immune system, urinary system diseases, blood-tumor diseases, mental illness.

2. Who has a history of hypersensitivity reactions to antifungal drugs including voriconazole or similar series or other excipient ingredients (aspirin, antibiotics, etc.)

3. Who has genetics issues on galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption

4. Who has a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (other than simple appendectomy and herniotomy)

5. A person whose electrocardiogram value includes QTc > 440 msec, PR < 110 msec or PR > 200 msec, QRS < 60 msec or QRS > 110 msec after screening, or who show clinically significant opinion.

6. Who falls under the following results

1. AST, ALT are exceeded over 1.5x the upper limit of the normal range

2. Total bilirubin is exceeded over 1.5x the upper limit of the normal range

7. Who shows the vital sign values of more than 140 mmHg or less than 90 mmHg in systolic pressure or more than 100 mmHg or less than 60 mmHg in diastolic blood pressure

8. Who has history of drug abuses or shows a positive result in the urinary drug screen

9. Who took any prescribed drugs, medicinal plants within the 2 weeks before the first day of dosing or takes any over-the-counter drugs or vitamin supplements within 1 week (but, if other conditions are met, they can still participate in the clinical test through the researcher's judgment)

10. Who took other investigational drugs or bioequivalence drugs within 3 months before the first day of dosing

11. Who participated in whole blood donation within 2 months before the first of dosing, or platelet donations within 1 months. Who received blood a month before the first day of dosing

12. Who constantly drinks alcohol (over 21 units/week, 1 unit = 10 g of pure alcohol) or cannot stop drinking alcohol during the clinical test.

13. Who smokes more than 10 cigarettes per day, or who cannot quit smoking when hospitalized

14. Who absorb caffeinated drinks (coffee, tea (black or green tea), soda, coffee flavored milk, energy drinks, etc.) or cannot stop absorbing them 24 hours before hospitalization until discharging

15. Who takes drug metabolism drug like barbital drugs which inhibit or activate the metabolism or drugs, or who takes one of the following drugs: St. John's Wort, rifabutin, rifampicin, carbamazepine, phenobarbital, high-dose of ritonavir, terfenadine, astemizole, cisapride, pimozide, quinidine, sirolimus, ergot, alkaloid (ergotamine, dihydroergotamine), efavirenz

16. Who was having foods (especially grapefruit or products contain grapefruit) that can influence the drug absorption, distribution, metabolism, and excretion within 7 days from the first day of dosage

17. A woman who is pregnant, shows positive result in serum/urine test, or who is breastfeeding

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Inha University Hospital

Incheon, , South Korea

Countries

South Korea

References

Cho SH, Kim CW, Nam MS. Pharmacokinetics and Safety of Two Voriconazole Formulations after Intravenous Infusion in Healthy Korean Volunteers. Infect Chemother. 2020 Jun;52(2):204-211. doi: 10.3947/ic.2020.52.2.204. Epub 2020 May 29.

Reference Type: DERIVED

PMID: 32468741 (View on PubMed)

Other Identifiers

151HPS14014

Identifier Type: -

Identifier Source: org_study_id